Company / SG&A per Share
Vertex Pharmaceuticals SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$6.82
FY2025
5-year range
$3.23 / $6.82
FY2021-FY2025
Trend
+20.1%
vs FY2024
Sector context
#25 of 210
Health Care
What the data says
Vertex Pharmaceuticals's sg&a per share of $6.82 is higher than 88% of companies in the Health Care sector (FY2025). SG&A per Share has increased for 9 consecutive years, from $1.76 in FY2016 to $6.82 in FY2025.
Based on SEC 10-K filings.
6.82 in FY2025 with a 5-year CAGR of +18.1%. Top quartile in the Health Care sector.
Increased from $4.42 to $6.82 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +22.5%
- 5-Year CAGR
- +18.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 210This company $6.82 Sector average $40.75
▼
-83.3% below sector average
Key checks
Key Insights
- Vertex Pharmaceuticals's sg&a per share has grown for 9 consecutive years.
- In FY2025, sg&a per share increased 20.1% year-over-year.
- Ranks #25 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.82 | +20.1% |
| FY2024 | $5.68 | +28.5% |
| FY2023 | $4.42 | +19.1% |
| FY2022 | $3.71 | +14.8% |
| FY2021 | $3.23 | +8.7% |
| FY2020 | $2.97 | +15.3% |
| FY2019 | $2.58 | +17.2% |
| FY2018 | $2.20 | +10.2% |
| FY2017 | $2.00 | +13.7% |
| FY2016 | $1.76 | +12.8% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026